Kornimate/medical-research-clean huggingface dataset:
comparative efficacy of iv dexamethasone vs. nebulized salbutamol for renal colic pain in the ed

Conditions: Renal Colic

Summary: adult patients (18-55 years of age) with clinical diagnosis of acute renal colic (sudden sharp colic flank pain with or without radiation to genitalia or groin and with or without urinary symptoms) who had pain score of 5 or more measured by 10-cm visual analogue scale (vas), will be included. will be excluded those who had history of cardiovascular, hepatic, renal or metabolic diseases, patients with evidence of sepsis or clinical suspicion of urinary tract infection, hemodynamically unstable patients (systolic blood pressure \&lt;90 mmhg), patients with uncontrolled diabetes, pregnancy, breastfeeding, patients unable to understand verbal and/or written information, patients receiving analgesics within 6 hours before presentation, serum potassium less than 3.7 mmol/l, concomitant use of any beta blockers (including beta-blocker containing eye drops), prolonged-release long-acting β-agonists, use of short-acting β2-agonists within the 6 h preceding presentation to the emergency department, any contraindication to the use of salbutamol, history of drug dependence or chronic consumption of alcohol. will be also excluded patients with known allergy to paracetamol or salbutamol, patients with abdominal tenderness as a sign of peritoneal inflammation and those with any clinical suspicion for diseases other than urolithiasis, including abdominal aortic aneurysm or dissection.


Eligibility criteria:
inclusion criteria: * adults aged 18-65 years * clinical diagnosis of acute renal colic (defined as sudden sharp colicky flank pain with or without radiation to the genitalia or groin, and with or without urinary symptoms) * pain score of 5 or more measured using the 10-cm nrs scale exclusion criteria: * history of cardiovascular, hepatic, renal, or metabolic diseases * evidence of sepsis or clinical suspicion of urinary tract infection * hemodynamically unstable (systolic blood pressure \< 90 mmhg) * uncontrolled diabetes * pregnancy or breastfeeding * inability to understand verbal and/or written information * received any analgesics within 6 hours prior to presentation * serum potassium \< 3.7 mmol/l * concomitant use of: any beta-blockers (including beta-blocker-containing eye drops) prolonged-release long-acting β-agonists short-acting β2-agonists within 6 hours prior to presentation * contraindication to salbutamol use * known allergy to paracetamol or salbutamol * abdominal tenderness suggestive of peritoneal inflammation * clinical suspicion of conditions other than urolithiasis, including: * abdominal aortic aneurysm * aortic dissection * history of drug dependence or chronic alcohol consumption

Keywords: renal colic salbutamol dexamethasone
efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in severe cardiac iron overload

Conditions: Cardiac Iron Overload

Summary: this study will evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed be deferasirox monotherapy in patients with severe iron overload due to chronic blood transfusions.


Eligibility criteria:
inclusion criteria: * patients with β-thalassemia major or diamond-blackfan anemia (dba) or congenital sideroblastic anemia on chronic transfusion therapy * myocardial t2\* value that is ≥ 5 and \< 10 ms * left ventricular ejection fraction (lvef) ≥ 56% as determined by magnetic resonance imaging (mri) * liver iron concentration (lic) ≥ 7 mg fe /g dw as determined by r2 mri. * lifetime history of at least 50 units of red blood cell transfusions, and must be receiving at least ≥ 8 units/yr of red blood cell transfusions * serum ferritin ≥ 1000 ng/ml exclusion criteria: * patients with clinical symptoms of cardiac dysfunction (shortness of breath at rest or exertion, orthopnea, exercise intolerance, lower extremity edema, arrhythmias) * patients unable to undergo study assessments including mri * patients with serum creatinine greater than upper limit of normal uln)range or with significant proteinuria as indicated by a urinary protein/creatinine ratio (upcr) ≥1.0 mg/mg in a non-first void urine sample at baseline. other protocol-defined inclusion/exclusion criteria may apply

Keywords: cardiac iron overload, deferasirox, deferoxamine
procalcitonin at zero and 24 hours as a prognostic factor in patients with pneumonia

Conditions: Pneumonia

Summary: procalcitonin levels checked initially and at 24 hours will correlate with disease severity, morbidity, and mortality. patients who have a higher procalcitonin level initially and at 24 hours will likely have higher qsofa scores, longer lengths of stay, longer duration of antibiotics and higher 30 day mortality rates.

a procalcitonin order bundle will be created for admitted patients with pneumonia. this prepopulated bundle includes an initial and 24 hour procalcitonin level, much like the current initial and 4 hour lactate orders are set-up. these patients will receive treatment for their pneumonia as is deemed appropriate by their care teams, both in the emergency department and while an inpatient. then, after discharge, the 30 day mortality, length of stay, choice of antibiotic therapy, and qsofa score (which will be retroactively calculated) will be compared to the patient's initial and 24 hour procalcitonin level.

Eligibility criteria:
inclusion criteria: * all patients seen at lakeland st. joseph and niles hospitals in the emergency department and who are then subsequently admitted with pneumonia at lakeland st. joseph and niles hospitals exclusion criteria: * any patients not admitted with pneumonia, any patients who are admitted with another primary diagnosis other than pneumonia, any patients who do not have an initial or 24 hour procalcitonin level result, and any patients less than 18 years old

Keywords: serial procalcitonin, admitted pneumonia, qsofa, sepsis
enhanced recovery after surgery (eras) for ambulatory turbt

Conditions: Bladder Cancer

Summary: this is a single-center, randomized-controlled trial to investigate the effectiveness of an eras protocol compared to usual care in patients with bladder cancer undergoing ambulatory turbt. the eras protocol is comprised of pre, intra and postoperative components designed to optimize each phase of perioperative care.


Eligibility criteria:
inclusion criteria: * patients with suspected or known bladder cancer * age \>= 18 years * undergoing initial or repeat turbt * ambulatory turbt with same day discharge home planned exclusion criteria: * undergoing a planned concomitant procedure * inability to consent for themselves * unable to complete telephone-based follow up after discharge home * undergoing active treatment for muscle-invasive bladder cancer

Keywords: eras ambulatory surgery quality of recovery quality of care bladder cancer patient-centered outcomes enhanced recovery after surgery
carotid duplex ultrasound for selecting patients for endovascular thrombectomy in acute stroke patients

Conditions: Stroke, Acute

Summary: the aim of this study is to address the usefulness of carotid duplex ultrasound as vascular imaging for selecting acute stroke patients for endovascular thrombectomy.


Eligibility criteria:
inclusion criteria: * endovascular treatment can be initiated within 6 hours of symptom onset. * aspects of \>=6 is diagnosed by two or more stroke physicians. * the end diastolic velocity in the common carotid arteries or internal carotid artery is evaluated by carotid duplex ultrasound * nihss score of \>=6. * age\>=18 years. * written informed consent is obtained. exclusion criteria: * pre-stroke modified rankin scale (mrs) score \>=2. * difficulties to evaluate aspects on initial ct. * difficulties to groin puncture. * history of severe allergic reaction to contrast medium. * end stage renal disease.
iron fortified beverages and application in women predisposed to anemia

Conditions: Iron-deficiency Anemia

Summary: * the objective of the study is to know if consumption of an iron fortified fruit juice containing micronized iron pyrophosphate, is useful to increase iron status in women predisposed to iron deficiency anemia. * a secondary objective is to know if consumption of this iron fortified fruit juice modifies bone remodelling.


Eligibility criteria:
inclusion criteria: * women * non-smoker * non-pregnant * non-breastfeeding * serum ferritin \<40 ng/ml * hemoglobin\>=11g/dl exclusion criteria: * serum ferritin \>=40 ng/ml * hemoglobin \<11g/dl * amenorrhea * menopause * iron deficiency anemia * thalassemia * hemochromatosis * blood donors * chronic gastric diseases * renal diseases * eating disorders * allergy to any component of the study juices * consumption of iron or ascorbic acid supplements within 4 month prior to participating in the study

Keywords: ferric pyrophosphate fortification fruit juice functional food bioavailability iron status women iron-deficiency anemia
the safety and effects of gefitinib in triple-negative,egfr positive metastatic breast cancer

Conditions: Breast Cancer

Summary: breast cancer is a heterogeneous disease and can be classified into several distinctive subgroups. triple-negative breast cancer(tnbc) is defined by lack of estrogen(er), progesterone(pr) immunoreactivity and lack of human epidermal receptor-2(her2) overexpression. tnbc comprises around 15% of all breast cancer and is characterized by its aggressive clinical behavior and insensitivity toward available targeted treatment strategies such as endocrine and anti-her2 therapies.although tnbc is sensitive to chemotherapy,early relapse with metastatic disease is common and the prognosis is poor. development of novel treatment strategies is,therefore,needed and the study of other potential targets in tnbc,like tyrosine kinase receptors,is a topic of interest. epidermal growth factor receptor(egfr) is a transmembrane receptor tyrosine kinase that encoded by cell erythroblastosis virus oncogene b1(c-erbb1) and belongs to the her/erythroblastosis virus oncogene b(erbb) family. by several signal pathways,egfr regulates cell proliferation, differentiation, apoptosis, invasion,and angiogenesis,and serves as a poor prognostic factor.egfr is overexpressed in a variety of malignancies including tnbc.gene expression profiling and immunohistochemical studies have indicated that 40 to 60% of tnbcs exhibit egfr expression and gene amplification was found in 18% of this subgroup,but egfr mutation was rare in tnbc. by far,the role of gefitinib, an egfr tyrosine kinase inhibitor(tki),in the metastatic tnbc has not been identified. most clinical trials about egfr tkis in the breast cancer have one or more limitations including:1) the study population had received heavily pretreatment; 2)the enrolled patients included several subgroups of breast cancer; 3)the expression of egfr was not clear in the enrolled patients. here, the investigators launch a prospective clinical trial, and about 50 patients with triple-negative,egfr positive metastatic breast cancer that have received at least second line therapy will be enrolled. these patients will be treated with gefitinib, the toxicity and effects of gefitinib will be recorded prospectively to evaluate the role of gefitinib in the metastatic tnbc.


Eligibility criteria:
inclusion criteria: * ≥18 years of age * ≥1 measurable or assessable lesion * eastern cooperative oncology group(ecog)performance status of 0-2 * adequate renal,hepatic and hematological function * a life expectancy of \>12 weeks * histologically proven egfr positive metastatic tnbc exclusion criteria: * brain metastasis

Keywords: triple-negative breast cancer epidermal growth factor receptor gefitinib
the affect of an anti-embolism stocking protocol

Conditions: Venous Thromboembolism

Summary: this study was conducted to determine the effect of anti-embolism stocking (aes) use protocol affected the development of early venous thromboembolism (vte) in patients undergoing total knee arthroplasty (tka). the randomized controlled single-blind intervention study included 40 patients (experimental group: 20, control group: 20) who underwent tka surgery in a university hospital's orthopedics and traumatology clinic between 2019 and 2021. while the experimental group received the aes protocol one day before the operation and continued until the 10 th day after the operation, the control group received aes on the 0 th day after the operation and remained in the patient until the 21st day after the operation. in the study, a "data collection form" with dvt and pe signs and symptoms was used.

the study was carried out at a university hospital's orthopedics and traumatology clinic. knee arthroplasty surgery is performed on an average of 85 patients per year in the hospital with a bed capacity of 1200. the orthopedics and traumatology clinic has 36 beds and 9 nurses on staff. in the clinic, lmwh is given to patients who will have knee arthroplasty 12 hours before the procedure. following knee arthroplasty, an elastic bandage is placed over the dressing on the operated extremity, and aes is only applied to the intact extremity. aes is dressed on both extremities after the elastic bandage is removed. foot movements begin on the first postoperative day, and patients are mobilized on the first or second postoperative day. patients are admitted to the clinic for a period of 5-7 days. lmwh application, which began in the preoperative period, continues in the postoperative period for approximately 21 days (until the sutures are removed). the aes usage protocol is not implemented in the clinic, and no training is provided to patients regarding the use of aes by healthcare personnel. after tka surgery, aes patients are dressed, and it is recommended that they wear them without removing them for 21 days (sutures are removed).

Eligibility criteria:
inclusion criteria: * older than 18 years old, * no harm in wearing aes, * patients who agreed to participate in the study. exclusion criteria: * bilateral tka used patients, * having excess leg edema, pulmonary edema, heart failure, * having leg ischemia, * having skin graft, * an open wound in the area where aes will be applied, * having arterial and venous vessel disease, * having neuropathy, * having cellulite on the patient's leg to whom aes will be applied, * having an infection such as fasciitis or panniculitis, * those who declare that they will not use aes for ten days in accordance with the recommendations.

Keywords: anti-embolism stockings knee arthroplasty nonpharmacological method orthopedic nursing venous thromboembolism
an observational study of patient cohorts who previously received long-term treatment with pioglitazone or placebo in addition to existing antidiabetic medications

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of this study was to investigate the mortality and macrovascular morbidity as well as the incidence of malignancies over time, in high-risk diabetic participants who previously received long-term treatment with either pioglitazone or placebo in combination with their usual medication for glycaemic management.

this was a european,multicenter,observational study of participants who were previously treated with pioglitazone or placebo in addition to their existing anti diabetic medication. this 10-year observational study was conducted as a follow-up of proactive study (nct00174993) to investigate the cv and macrovascular effects observed with pioglitazone over time during proactive.in this study,high risk t2dm patients previously enrolled in proactive were analyzed for long-term incidence,nature, and pattern of all malignancies in pioglitazone and placebo-treated groups.this study enrolled 3599 participants.no treatment was prescribed by this protocol and participants will be managed in accordance with normal medical practice.the planned total duration of the study was 10 years,with data being analyzed and reported every 2 years.participants were assessed at nominal visits every 6 months and every effort was made to obtain as much of the required information as possible.

Eligibility criteria:
inclusion criteria: * completion of the final visit of the proactive study (nct00174993). * willingness and ability to give written informed consent for the observational study. exclusion criteria: * there were no exclusion criteria.

Keywords: drug therapy
analysis of outcomes and adverse events of patients undergoing radiation therapy

Conditions: Radiotherapy; Adverse Effect; Radiotherapy; Complications; Quality of Life

Summary: analysis of outcomes and adverse events of patients undergoing radiation therapy. quality control using data base of patient records 2000-2025

what are the findings of the systematic recording and analysis of the outcomes and adverse events of radiotherapy, and how do these findings improve radiotherapy for future patients? the goals of the systematic collection and analysis of patient-related personal data include: * quality assurance and showing where the quality can be improved * recording the outcomes and side effect profile of radiotherapy and adapting to prevent serious side effects in the future * presentation and publication as part of the clinical research program at the institute for radio-oncology of the winterthur cantonal hospital

Eligibility criteria:
inclusion criteria: * patients who are being treated with radiotherapy at the department of radiation oncology at the winterthur cantonal hospital exclusion criteria: * no radiotherapy at the department of radiation oncology at the winterthur cantonal hospital \ 105 years
sovaldi-based regimens in patients in mexico with chronic hepatitis c virus infection in clinical practice

Conditions: HCV Infection

Summary: this study will collect and evaluate information on the safety and efficacy of sovaldi-based regimens in routine clinical practice in mexico. the primary objective of this study is to assess the rates of serious adverse events/reactions (saes/sadrs) and adverse events/reactions (aes/adrs) in adult participants with chronic hepatitis c virus (hcv) infection treated with sovaldi in routine clinical practice.


Eligibility criteria:
key inclusion criteria: * hcv-infected patients living in mexico * treatment with a sovaldi-based regimen, per the approved prescribing information, as determined by the patient's treating physician key exclusion criteria: * concurrent participation in an hcv clinical trial (except trials not testing investigational medicinal products) * patients presenting a risk of not being able to be followed (eg, patients planning to move or leave the country prior to their svr12 visit) note: other protocol defined inclusion/exclusion criteria may apply.
optimizing endobronchial ultrasound sampling for molecular markers for nsclc

Conditions: Lung Cancer; Non Small Cell Lung Cancer; Circulating Tumor Cell

Summary: in this monocentric randomized controlled trial, 120 potential non small cell lung cancer (nsclc) patients for which tissue diagnosis and material for next generation sequencing (ngs) is required for clinical management will be approached the day of their endobronchial ultrasound to participate in the study. they will be randomized to 2 vs 3 passes/lymph node and will all undergo liquid biopsy. the co-primary outcomes are 1)the rate of obtention of adequate material for ngs testing with 2 vs 3 passes/lymph node and 2)the percentage of patients for which liquid biopsy allows to identify clinically pertinent findings not available from tissue biopsy


Eligibility criteria:
inclusion criteria: * suspected or confirmed nsclc requiring tissue sample for ngs testing to guide clinical management * presence of at least 2 targets accessible by ebus or eus suspicious of malignancy (primary tumor, lymph node \> 10mm or with standardized uptake value (suv) \> 2.5) exclusion criteria: * other modality then ebus judged preferable by treating physician to obtain tumoral tissue for ngs testing
temperature sensitive release of pge2 and diminished energy requirements in synovial tissue with postoperative cryotherapy - a prospective randomised study after knee arthroscopy

Conditions: Knee Arthroscopy; Meniscus; Inflammation; Hydrops; Cooling

Summary: abstract background: local external cooling of the postoperative field is a treatment paradigm aiming for enhanced recovery after joint surgery. it is supposed to reduce pain and improve mobilization, enabling same day surgery. hypothesis: systematic postoperative cooling and compression after knee arthroscopy will reduce pain and also be reflected by changes in local levels of metabolic and inflammatory variables in the synovial membrane. study design: prospective randomised study; level of evidence 1. methods: forty-four otherwise healthy patients were included in the study and randomised to systematic cooling and compression or no cooling and compression after knee arthroscopy. microdialysis of the synovial membrane was performed postoperatively with measurements of pge2, glucose, lactate, glycerol, glutamate and blood flow (ethanol exchange ratio). local temperature was monitored as well as postoperative pain (vas and nrs). results: the application of a cooling and compression device after knee arthroscopy resulted in significantly lower temperature in the operated knee (skin, joint capsule and intraarticularly). the cooling and compression diminished energy requirements in synovial tissue and a 3 temperature sensitive influence on inflammation (pge2) were shown. no effect on postoperative pain was detected. conclusion: local cryotherapy and compression after knee arthroscopy significantly lowered local knee temperature postoperatively. a correlation with synovial pge 2 and temperature was shown. since pge2 is a pain and inflammatory marker this implicates a positive anti-inflammatory effect induced by postoperative local cooling and compression. hypothermia is proposed to have a protective effect in ischemic tissue. this is probably due to a decreased metabolic rate and therefore decreased energy requirements as shown by stable levels of lactate despite lower blood flow indicated by increasing ethanol ratio.


Eligibility criteria:
inclusion criteria: * indication for knee arthroscopy due to suspected meniscus injury exclusion criteria: * osteoarthritis or known systemic inflammatory disease, eg ra

Keywords: inflammation arthroscopy knee microdialysis